Addex Therapeutics (ADXN) announced that the last patient has been randomized in Cohort 2 of the ADX71149 Phase 2 epilepsy clinical study. Results evaluating the efficacy, safety and tolerability of ADX71149 in combination with levetiracetam or brivaracetam from patient Cohorts 1 and Cohort 2 are anticipated for the second quarter of 2024. The primary efficacy endpoint of this study is time to baseline monthly seizure count. The trial is being conducted in collaboration with Janssen Pharmaceuticals, a Johnson & Johnson (JNJ) company. As previously announced on May 10, an independent Interim Review Committee, or IRC, convened by Janssen recommended to continue the study following review of unblinded data from Part 1 of patient Cohort 1.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ADXN:
- Addex Therapeutics regains compliance with Nasdaq
- Addex Therapeutics announces one for twenty reverse ADS split
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue